BACKGROUND: Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50-999 copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are few or no data available demonstrating that HIV-1 drug resistance testing at a plasma viral load (pVL) <1000 copies/mL provides potentially clinically useful information. Here, we assess the ability to perform resistance testing by genotyping at LLV and whether it is predictive of future virologic outcomes in patients beginning ART. METHODS: Resistance testing by genotyping at LLV was attempted on 4915 plasma samples from 2492 patients. A subset of previously ART-naive patients was analyzed who achieved undetectable pVL and subsequently rebounded with LLV (n = 212). A genotypic sensitivity score (GSS) was calculated based on therapy and resistance testing results by genotyping, and stratified according to number of active drugs. RESULTS: Eighty-eight percent of LLV resistance assays produced useable sequences, with higher success at higher pVL. Overall, 16 of 212 (8%) patients had pretherapy resistance. Thirty-eight of 196 (19%) patients without pretherapy resistance evolved resistance to 1 or more drug classes, primarily the nucleoside reverse transcriptase (14%) and/or nonnucleoside reverse transcriptase (9%) inhibitors. Patients with resistance at LLV (GSS <3) had a 2.1-fold higher risk of virologic failure (95% confidence interval, 1.2- to 3.7-fold) than those without resistance (P = .007). Progressively lower GSS scores at LLV were associated with a higher increase in pVL over time (P < .001). Acquisition of additional resistance mutations to a new class of antiretroviral drugs during LLV was not found in a subset of patients. CONCLUSIONS: Routine HIV-1 genotyping of LLV samples can be performed with a reasonably high success rate, and the results appear predictive of future virologic outcomes.
BACKGROUND: Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50-999 copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are few or no data available demonstrating that HIV-1 drug resistance testing at a plasma viral load (pVL) <1000 copies/mL provides potentially clinically useful information. Here, we assess the ability to perform resistance testing by genotyping at LLV and whether it is predictive of future virologic outcomes in patients beginning ART. METHODS: Resistance testing by genotyping at LLV was attempted on 4915 plasma samples from 2492 patients. A subset of previously ART-naive patients was analyzed who achieved undetectable pVL and subsequently rebounded with LLV (n = 212). A genotypic sensitivity score (GSS) was calculated based on therapy and resistance testing results by genotyping, and stratified according to number of active drugs. RESULTS: Eighty-eight percent of LLV resistance assays produced useable sequences, with higher success at higher pVL. Overall, 16 of 212 (8%) patients had pretherapy resistance. Thirty-eight of 196 (19%) patients without pretherapy resistance evolved resistance to 1 or more drug classes, primarily the nucleoside reverse transcriptase (14%) and/or nonnucleoside reverse transcriptase (9%) inhibitors. Patients with resistance at LLV (GSS <3) had a 2.1-fold higher risk of virologic failure (95% confidence interval, 1.2- to 3.7-fold) than those without resistance (P = .007). Progressively lower GSS scores at LLV were associated with a higher increase in pVL over time (P < .001). Acquisition of additional resistance mutations to a new class of antiretroviral drugs during LLV was not found in a subset of patients. CONCLUSIONS: Routine HIV-1 genotyping of LLV samples can be performed with a reasonably high success rate, and the results appear predictive of future virologic outcomes.
Authors: Conar R O'Neil; Alexis K Palmer; Suzy Coulter; Nadia O'Brien; Anya Shen; Wendy Zhang; Julio S G Montaner; Robert S Hogg Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2012-02-07
Authors: Jonathan Z Li; Sebastien Gallien; Tri D Do; Jeffrey N Martin; Steven Deeks; Daniel R Kuritzkes; Hiroyu Hatano Journal: Antimicrob Agents Chemother Date: 2012-08-13 Impact factor: 5.191
Authors: Margriet Van Houtte; Gaston Picchio; Koen Van Der Borght; Theresa Pattery; Pierre Lecocq; Lee T Bacheler Journal: J Med Virol Date: 2009-10 Impact factor: 2.327
Authors: L Bansi; C Sabin; V Delpech; T Hill; M Fisher; J Walsh; T Chadborn; P Easterbrook; R Gilson; M Johnson; K Porter; J Anderson; M Gompels; C Leen; J Ainsworth; C Orkin; M Nelson; B Rice; A Phillips Journal: HIV Med Date: 2010-02-08 Impact factor: 3.180
Authors: Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Judith Feinberg; Karen Tashima; Robert L Murphy; Margaret A Fischl Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: Clin Infect Dis Date: 2010-01-01 Impact factor: 9.079
Authors: Bianca Bruzzone; Antonio Di Biagio; Laura Sticchi; Renata Barresi; Francesco Saladini; Giancarlo Icardi; Maurizio Setti Journal: Antimicrob Agents Chemother Date: 2014-12 Impact factor: 5.191
Authors: Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla Journal: J Infect Dis Date: 2019-07-19 Impact factor: 5.226
Authors: Joseph J Eron; David A Cooper; Roy T Steigbigel; Bonaventura Clotet; Patrick Yeni; Kim M Strohmaier; Anthony J Rodgers; Richard J Barnard; Bach-Yen T Nguyen; Hedy Teppler Journal: Antivir Ther Date: 2014-10-27
Authors: Viviane D Lima; Anja Reuter; P Richard Harrigan; Lillian Lourenço; William Chau; Mark Hull; Lauren Mackenzie; Silvia Guillemi; Robert S Hogg; Rolando Barrios; Julio S G Montaner Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: H R Lapointe; W Dong; G Q Lee; D R Bangsberg; J N Martin; A R Mocello; Y Boum; A Karakas; D Kirkby; A F Y Poon; P R Harrigan; C J Brumme Journal: Antimicrob Agents Chemother Date: 2015-08-17 Impact factor: 5.191
Authors: Christopher F Lowe; Linda Merrick; P Richard Harrigan; Tony Mazzulli; Christopher H Sherlock; Gordon Ritchie Journal: J Clin Microbiol Date: 2015-11-04 Impact factor: 5.948